Toxin gene-mediated growth inhibition of lung adenocarcinoma in an animal model of pleural malignancy

被引:1
作者
Hoganson, DK [1 ]
Matsui, H [1 ]
Batra, RK [1 ]
Boucher, RC [1 ]
机构
[1] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA
关键词
D O I
10.1089/hum.1998.9.8-1143
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Transduction of malignant cells with toxin genes provides a novel strategy by which to promote tumor cell destruction. Whereas the capacity of the toxin gene/prodrug combination cytosine deaminase/fluorocytosine to inhibit growth of human metastatic pulmonary adenocarcinoma cell lines in vitro is established, the in vivo efficacy of this binary system has not yet been determined, For the development of toxin gene therapy for the treatment of lung adenocarcinoma metastatic to the pleural space, a reliable, disease-specific model is required, The serosa of the rat small intestine resembles the basal lamina of the pleura and provides the basis for a more convenient model than direct injection of tumor into the pleural space, Adenocarcinoma cells are innoculated into everted denuded rat intestine configured as a sac, Immunocytochemical and histological analyses show rapid cell growth with characteristics that mimic nodular metastatic intrapleural disease, In the context of this model, systemically delivered fluorocytosine significantly inhibits the growth of cytosine deaminase-expressing human lung adenocarcinoma cells, The dosing schedule required 30 days; neither addition of an enzyme inhibitor that increases the half-life of fluorocytosine nor intralumenal drug delivery is effective in shortening (to 15 days) the protocol, We conclude that CD continues to hold promise as a toxin gene for lung adenocarcinoma gene therapy, and that prolonged prodrug administration may be required for maximum efficacy.
引用
收藏
页码:1143 / 1156
页数:14
相关论文
共 27 条
[1]   5-ETHYNYLURACIL (776C85) - A POTENT MODULATOR OF THE PHARMACOKINETICS AND ANTITUMOR EFFICACY OF 5-FLUOROURACIL [J].
BACCANARI, DP ;
DAVIS, ST ;
KNICK, VC ;
SPECTOR, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11064-11068
[2]  
BATRA RK, 1996, AM J RESP CRIT CARE, V153, pA111
[3]  
CONSALVO M, 1995, J IMMUNOL, V154, P5302
[4]  
COOPER D, 1985, LAB INVEST, V52, P243
[5]   CLINICAL PHARMACOKINETICS OF SYSTEMIC ANTI-FUNGAL DRUGS [J].
DANESHMEND, TK ;
WARNOCK, DW .
CLINICAL PHARMACOKINETICS, 1983, 8 (01) :17-42
[6]   INVIVO RETROVIRAL GENE-TRANSFER INTO HUMAN BRONCHIAL EPITHELIA OF XENOGRAFTS [J].
ENGELHARDT, JF ;
YANKASKAS, JR ;
WILSON, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) :2598-2607
[7]  
Ginsberg Robert J., 1997, P858
[8]  
HEGGIE GD, 1987, CANCER RES, V47, P2203
[9]   IN-VIVO ADENOVIRUS-MEDIATED GENE-TRANSFER OF THE ESCHERICHIA-COLI CYTOSINE DEAMINASE GENE TO HUMAN COLON CARCINOMA-DERIVED TUMORS INDUCES CHEMOSENSITIVITY TO 5-FLUOROCYTOSINE [J].
HIRSCHOWITZ, EA ;
OHWADA, A ;
PASCAL, WR ;
RUSSI, TJ ;
CRYSTAL, RG .
HUMAN GENE THERAPY, 1995, 6 (08) :1055-1063
[10]  
Hoganson DK, 1996, CANCER RES, V56, P1315